由于诉讼仍处于初步阶段，进一步详情(包括可能索偿金额)仍须视诉讼结果而定。公司将根据香港联合 交易所有限公司证券上市规则的规定于适当时候就诉讼的任何实质进展作出进一步公告。 启明医疗-B(02500)发布公告，于2025年6月9日，美国联邦巡回上诉法院作出判决，确认由Cardiovalve Ltd.拥有的美国专利第10,702,385号(心脏瓣膜植入物)(美国第385号专利)中若干权利要求具专利有效性， 而Edwards Lifesciences Corp.及Edwards Lifesciences LLC(统称"Edwards")曾于2021年六月在专利双方复 审程序中对该专利提出质疑。于2026年1月14日，Cardiovalve Ltd.与MTH IP,L.P.就美国第385号专利于美 国特拉华州地区法院对Edwards提起专利侵权诉讼，指控Edwards的核心产品PASCAL Precision经导管瓣 膜修复系统侵犯Cardiovalve Ltd.所持有的美国第385号专利。 ...

智通财经APP讯，启明医疗-B(02500)发布公告，于2025年6月9日，美国联邦巡回上诉法院作出判决，确 认由Cardiovalve Ltd.拥有的美国专利第10,702,385号(心脏瓣膜植入物)(美国第385号专利)中若干权利要 求具专利有效性，而Edwards Lifesciences Corp.及Edwards Lifesciences LLC(统称"Edwards")曾于2021年 六月在专利双方复审程序中对该专利提出质疑。于2026年1月14日，Cardiovalve Ltd.与MTH IP, L.P.就美 国第385号专利于美国特拉华州地区法院对Edwards提起专利侵权诉讼，指控Edwards的核心产品 PASCAL Precision经导管瓣膜修复系统侵犯Cardiovalve Ltd.所持有的美国第385号专利。 由于诉讼仍处于初步阶段，进一步详情(包括可能索偿金额)仍须视诉讼结果而定。公司将根据香港联合 交易所有限公司证券上市规则的规定于适当时候就诉讼的任何实质进展作出进一步公告。 ...

Core Viewpoint - The article highlights that Qiming Medical-B (02500) has initiated a patent infringement lawsuit against Edwards Lifesciences in the U.S., marking a significant step in the company's legal strategy to protect its intellectual property rights and enhance its competitive position in the global medical device market [1]. Group 1: Company Actions - Qiming Medical's subsidiary Cardiovalve has filed a lawsuit in the U.S. District Court of Delaware against Edwards, alleging that its PASCAL Precision transcatheter valve repair system infringes on Cardiovalve's U.S. Patent No. 10,702,385 [1]. - This legal action follows Qiming Medical's previous victory in July 2025, where it successfully upheld the validity of its US'385 patent against Edwards [1]. Group 2: Industry Implications - Analysts view this lawsuit as a proactive measure by Qiming Medical to defend its innovations, representing a milestone for Chinese medical device companies in leveraging a robust intellectual property system for global market competition [1].

Core Viewpoint - The article highlights that Qiming Medical's subsidiary Cardiovalve has filed a patent infringement lawsuit against Edwards Lifesciences in the U.S., marking a significant step in the company's legal strategy to protect its intellectual property rights and enhance its competitive position in the global medical device market [1]. Group 1: Company Actions - Qiming Medical's stock price increased by over 14% during trading, with a current price of HKD 3.65 and a trading volume of HKD 26.28 million [1]. - The lawsuit was filed in the Delaware District Court, accusing Edwards of infringing on Cardiovalve's U.S. Patent No. 10,702,385 related to its PASCAL Precision transcatheter valve repair system [1]. Group 2: Industry Implications - Analysts view this legal action as a proactive measure by Qiming Medical following its previous victory in July 2025 regarding the validity of the US'385 patent, emphasizing the importance of intellectual property in the competitive landscape of the medical device industry [1]. - This case is seen as a milestone for Chinese medical device companies in their globalization efforts, showcasing the role of a robust intellectual property system in market competition [1].

Core Viewpoint - Edwards Lifesciences continues to showcase its commitment to the structural heart disease field by participating in the China International Import Expo for the sixth consecutive year, highlighting its innovative products and treatment solutions [1] Group 1: Product Launch and Innovation - Edwards Lifesciences presented the PASCAL Precision transcatheter valve repair system, marking its debut at the expo following its launch in Hong Kong [1] - The PASCAL Precision system offers a minimally invasive and reliable intervention option for high-risk surgical patients with mitral and tricuspid regurgitation, with expectations for approval in mainland China next year [1] Group 2: Strategic Partnerships - Edwards has upgraded its strategic collaborations with key industry partners such as Sinopharm Group and Shanghai Pharmaceuticals, aiming to enhance the introduction of advanced technologies and clinical transformation [1] - Wayne Markowitz, Global Vice President for Japan and Asia Pacific, emphasized the company's patient-first philosophy and the importance of the expo as a platform for collaboration [1] Group 3: Market Expansion - The participation in the expo signifies Edwards' efforts to accelerate the extension of its innovative achievements in transcatheter valve repair to the Chinese market [1] - The company aims to leverage the expo as an open window for accelerating the introduction of cutting-edge technologies [1]

Core Insights - The healthcare industry is demonstrating remarkable resilience in response to changing times, with a projected global market growth of 9% in 2024 driven by innovations in specialized treatments, explosive growth in anti-obesity drugs, and widespread application of AI in healthcare [1] - The China International Import Expo (CIIE) serves as a vital platform for global pharmaceutical companies to integrate deeply with the Chinese market and advance the Healthy China strategy [1][2] Industry Trends - The Chinese government has introduced policies to develop the healthcare industry and encourage innovative drug research, positioning China as a potential global center for biopharmaceutical innovation [2] - Major chronic diseases, such as cardiovascular and chronic kidney diseases, pose significant public health challenges in China, with over 400 million patients affected [2] Innovations and Product Launches - At the CIIE, various pharmaceutical companies showcased innovations across multiple fields, including cardiovascular, metabolic, respiratory, and oncology, highlighting their commitment to addressing major health challenges [1] - Novartis introduced the "Heart and Kidney Guardian Evidence-Based Science Popularization" project, emphasizing the dual role of pharmaceutical companies in drug development and public health education [3] - Sanofi launched two innovative cardiovascular drugs, Aficamten and Plerixafor, at the CIIE, addressing unmet patient needs in the treatment of cardiovascular diseases [3] - Roche presented advancements in blood cancer treatments, including new indications for existing therapies and innovative products for hemophilia [5] Strategic Collaborations - Siemens Healthineers and Novartis signed a strategic cooperation agreement to advance the integration of radioligand therapy and molecular imaging systems for precision treatment of diseases like prostate cancer [19] - Novo Nordisk and the Shanghai Clinical Innovation and Translation Research Institute (ACITS) established a strategic partnership to enhance clinical research and innovation in China [16][17] Public Health Initiatives - The CIIE featured discussions on the application of digital technology and AI in public health, aligning with China's "Healthy China 2030" strategy [21][23] - Pfizer emphasized the role of big data and AI in transforming public health systems and achieving health goals in China [23] Emerging Companies and Products - Viseon Pharmaceuticals showcased two innovative drugs at the CIIE, highlighting its commitment to global innovation and rapid market entry in China [24]